Back to Search
Start Over
Bayer and Onyx initiate pivotal phase III clinical trial in kidney cancer.
- Source :
- PharmaWatch: Cancer; December 2003, Vol. 2 Issue 12, p24-24, 1p
- Publication Year :
- 2003
-
Abstract
- Reports that Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals have begun in 2003 an international, multi-center phase III trial to further evaluate the safety and efficacy of the investigational drug BAY 43-9006, a novel signal transduction inhibitor, in the treatment of advanced renal cell carcinoma. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on cancer research.
Details
- Language :
- English
- Volume :
- 2
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- PharmaWatch: Cancer
- Publication Type :
- Report
- Accession number :
- 13778220